Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Suicide Associated With Sanofi-Aventis’ Acomplia, U.K. Agency Says

This article was originally published in The Pink Sheet Daily

Executive Summary

One suicide and 48 suicidal ideation cases reported following treatment with Acomplia between June 2006 and May 9.

You may also be interested in...



FDA Drops “Suicidality” Term, Urges Broader Risk Assessment During Development

Revised draft guidance retains eight categories of drugs to be evaluated for suicidal ideation and behavior in clinical trials, but says assessments could be conducted more broadly and “encourages” sponsors to discuss the possibility with the review division.

Sanofi’s Rimonabant Off The European Market; CHMP Finds Risk Management Plan Does Not Adequately Address Depression

Acomplia use doubles risk of psychiatric disorders in overweight patients, European review finds.

Sanofi’s Rimonabant Off The European Market; CHMP Finds Risk Management Plan Does Not Adequately Address Depression

Acomplia use doubles risk of psychiatric disorders in overweight patients, European review finds.

Related Content

Topics

UsernamePublicRestriction

Register

PS068023

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel